DOCSLIB.ORG

Kaposi's Sarcoma and Psoriasis in a Naïve HIV-Positive Patient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kaposi's Sarcoma and Psoriasis in a Naïve HIV-Positive Patient INFECT DIS TROP MED 2019; 5: E569 Kaposi’s Sarcoma and Psoriasis in a naïve HIV-positive patient: a case report F. D’Andrea1, A. Facciolà1, M. G. Coco1, C. Micali1, I. Paolucci2, D. Maranto2, M. R. Lo Presti Costantino2, D. Larnè1, P. Mondello2, G. F. Pellicanò3 1Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy 2Unit of Infectious Diseases, “G. Martino” University Hospital, Messina, Italy 3Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, University of Messina, Messina, Italy ABSTRACT: The introduction of combined Anti-Retroviral Therapy has modified the natural history of Hu- man Immunodeficiency Virus (HIV) infection, leading to an increase in life expectancy of the patients living with HIV. Immune deficiency can lead to opportunistic infections and an increased risk of autoimmune dis- ease and malignancy. Here we describe the case of a patient affected by psoriasis, HIV infection and Kapo- si’s Sarcoma. — Keywords: Kaposi’s Sarcoma, Human Immunodeficiency Virus, Psoriasis. INTRODUCTION CASE REPORT The introduction of combined Anti-Retroviral Therapy A 37-year-old man, from Sri-Lanka, was accompanied (cART) has modified the natural history of Human Immu- to the clinic of Infectious Diseases of the “G. Marti- nodeficiency Virus (HIV) infection, leading to an increase no” University Hospital in Messina (Messina, Italy) in life expectancy of the patients living with HIV (PLWH)1- because of a Kaposi’s Sarcoma in nodular phase con- 21. However, it is not able to eliminate the virus22-24. firmed by biopsy. He referred to the dermatologic clin- cART has brought an increased survival and a re- ic for a psoriasis vulgaris poorly responsive to cyclo- duced mortality for Acquired Immune Deficiency Syn- phosphamide. drome (AIDS)-related diseases25-28. An oral HIV test was performed, resulting positive. Many of the clinical features of HIV/AIDS can be This test was followed by a serological confirmatory ascribed to the immune deficiency developed by infect- test. Among the risk factors for the infection, he report- ed patients. The progressive destruction of the immune ed multiple unprotected homosexual relations since the system leads to opportunistic infections, as well as an in- age of 17. creased risk of autoimmune disease and malignancy29-35. He complained of cough, burning pain in the left leg Kaposi’s sarcoma (KS) is a multifocal angio-prolifer- and itch. Upon arrival, physical examination revealed ative neoplasm characterized by reddish-purple-brown multiple psoriatic plaques and numerous nodular and papules, plaques, and nodules20. Its clinical heterogene- macular lesion all over the body, especially on legs and ity depends on the host immune system20,21. Moreover, arms. Submandibular, laterocervical, supraclavicular HIV-positive patients are commonly affected by skin and inguinal lymphadenopathies were appreciable bilat- disorders, which are often associated with high morbidi- erally. He was then admitted to the Infectious Diseases ty and mortality36. HIV infection and psoriasis share the ward with the diagnosis of Kaposi’s Sarcoma and AIDS. chronic inflammatory status, that can induce some neo- He was not febrile (temperature 36.0°C), his heart rate plastic processes37-47. We describe the case of a patient (HR) was 60 beat per minute (bpm) and his blood pres- with Kaposi’s Sarcoma, HIV infection and Psoriasis. sure (BP) 120/60 mmHg. CORRESPONDING AUTHOR: GIOVANNI FRANCESCO PELLICANÒ, MD; [email protected] 1 INFECT DIS TROP MED Blood tests performed showed a white blood cell DISCUSSION (WBC) count of 3,200 cells/µL, with 46% of neutrophils and 46% of lymphocytes. Procalcitonin (PCT; 0.04 ng/ Despite its occurrence has dramatically decreased in de- ml, normal values < 0.1 ng/mL), and C Reactive Protein veloped countries, KS is still the most frequent tumor in (CRP; 0.09 mg/dL, normal values < 0.5 mg/dL) were HIV-infected patients worldwide33. The widespread use normal. HIV viral load was 65,000 copies/ml and CD4+ of antiretroviral therapy has reduced KS incidence, but T lymphocytes count was 10% (147/µL). Renal and liv- its prevalence is still high in sub-Saharan Africa, while er function tests resulted negative (creatinine 0.6 mg/ is quite uncommon in Europe and in United States of dL, normal values 0.5-1.2 mg/dL; total bilirubin 1.1 mg/ America (USA). The incidence of KS is 1/100,000 in dL, normal values < 1.2 mg/dL; aspartate aminotrans- the general population, whereas in HIV-infected indi- ferase, AST, 15 U/L, normal values < 42 U/L; alanine viduals it is around 1/2020,33. Moreover, the prevalence aminotransferase, ALT, 15 U/L, normal values < 50 in Men who have Sex with Men (MSM) is much high- U/L). Ferritin was 847 mg/dl, LDH 373 U/L, β2 Micro- er than general population. KS is caused by the Human globulin 3541 mg/dl. Antiretroviral therapy (ART) with Herpesvirus 8 (HHV8), also known as Kaposi Sarco- emtricitabine/tenofovir alafenamide fumarate 200/25 ma-associated Herpes Virus (KSHV)33. mg and dolutegravir 50 mg daily was promptly start- KSHV (HHV8) is a herpesvirus belonging to the ed. Trimethoprim/Sulfamethoxazole 160/800 mg daily gamma-herpesvirus family which is able to estab- was started in primary prophylaxis for toxoplasmosis. lish persistent infections, especially in the lymphoid QuantiFERON-TB test was performed, resulting neg- cells20,23. In conditions characterized by immune defi- ative. Serologies for Leishmania, Toxoplasma, Cito- ciency, such as transplant and HIV-infection, KSHV megalovirus, Ebstein Barr Virus, Hepatitis (A, B, C), can cause lymphoproliferative disorders such as KS, Herpes-Simplex 1 and 2, Syphilis, Measles, Rubella and Primary Effusion Lymphoma (PEL) and Multicentric Mumps were negative. He underwent a RX scan of the Castleman Disease (MCD)20. chest, which did not show parenchymal lesions, and a The majority of cases of KS occur in late phases brain MRI which showed the presence of inhomogene- of the HIV-infection with low CD4+ T-cell counts (< ity of submandibular glands, multiple lymphadenopathy 200/ml), although it has also been observed in patients in the laterocervical and sub-angolomandibular area. on successful long-term HAART, with well-controlled Colonoscopy and gastroscopy showed no visceral le- HIV-infection and a CD4+ T cell count > 200/ml20,33. sions. CT scan of neck, abdomen and chest showed mul- KSHV may be secreted in saliva. Even though saliva tiple lymphadenopathy in all latero-cervical, supracla- is considered the principal transmission way, KSHV can vicular, axillary, aorto-caval, iliac- obturator, inguinal be isolated from several other fluids and cells, including stations. Echocardiography was normal. The ultra- semen, cervicovaginal secretions, prostate glands and sound of the abdomen showed a markedly increased peripheral blood mononuclear cells (PBMCs). Other spleen volume. Suspecting a lymphoma, lymph node KSHV transmission ways can be blood transfusions and excision was performed. Three days after the surgical solid organ transplantations (SOT)20. excision, fever and incoercible hiccups occurred. Mul- In MSM, a high rate of KSHV transmission occurs tiple blood cultures for bacteria and fungi were per- even when safe sex practices are used. Important routes formed, resulting negative. The main microbiological of spread among MSM is probably the use of saliva as tests were repeated, and they were still negative. An- a lubricant during anal sex, oral-anal sex, and deep oral timicrobial therapy with piperacilline/tazobactam and kissing34,35. linezolid was promptly started. HIV viral load was Psoriasis is a chronic, multisystem inflammatory 240 copies/ml and CD4+ T lymphocytes count was disease with predominantly skin and joint involve- 24% (245/mmc) after 24 days of treatment. Despite a ment. As a disease of systemic inflammation, psoriasis good viro-immunological control, high temperature is associated with multiple comorbidities, including persisted, with max peaks of 39.6°C, and his general cardiovascular disease and malignancy37. Its pathogen- clinical conditions did not improve. Psoriatic plaques esis is multifactorial, involving dysregulated inflam- were intensely itchy, hiccups persisted, dry cough mation and genetic associations37,38. Psoriasis affects worsened. The abdomen was globose, meteoric, dis- PLWH severely and for a longer time than the gener- tended. Anti-microbial therapy with Piperacilline/Ta- al population36. Th1 cells and related cytokines play zobactam and Linezolid was stopped and Meropenem, a major role in the pathogenesis. Treatments that are Ceftobiprole and Fluconazole were started. Despite intended to suppress the T cell response may trigger the antimicrobial therapy, the general conditions of the the development of iatrogenic KS by causing immu- patient were still severe: it was then decided to start nosuppression39. In the case reported by Selvi et al40 the antimicrobial therapy with Ceftazidime/Avibactam the authors suggest that the worsening of KS lesions and Colistine. After few days, his general conditions despite discontinuation of systemic immunosuppres- progressively improved: the patient was alert, oriented sive therapy might have been related to intra-articu- in time and space, collaborative, afebrile and eupneic. lar steroid therapy administered for psoriatic arthritis. His cough and hiccups improved. We discharged the Furthermore, in a KS patient with severe psoriasis and patient after 30 days of admission in good clinical con- a history of phototherapy, the authors suggested that ditions. He is now in follow up for his Kaposi’s Sarco- the occurrence of psoriasis and KS may be related to a 2 ma, psoriasis and HIV infection. common genetic basis (HLA A1, DR5, DR7, and DR11) PSORIASIS, HIV AND KAPOSI’S SARCOMA and that phototherapy may trigger virus activation and 8. Pinzone MR, Gussio M, Bellissimo F, Coco C, Bisicchia F, KS lesions41. Erdoğan et al39 considered that psoriasis Pellicanò G, Palermo F, Mughini MT, Cacopardo B, Nunnari might have triggered KS development by causing im- G, Celesia BM. Self-reported sexual dysfunction in HIV- positive subjects: a cross-sectional study.
Load more

Recommended publications
  • Mmrv Vaccine
    VACCINE INFORMATION STATEMENT (Measles, Mumps, Many Vaccine Information Statements are available in Spanish and other languages. MMRV Vaccine Rubella and See www.immunize.org/vis Varicella) Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis These are recommended ages. But children can get the Measles, Mumps, Rubella and second dose up through 12 years as long as it is at least 1 Varicella 3 months after the first dose. Measles, Mumps, Rubella, and Varicella (chickenpox) can be serious diseases: Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and Measles varicella vaccines. • Causes rash, cough, runny nose, eye irritation, fever. • Can lead to ear infection, pneumonia, seizures, brain 1 Shot (MMRV) or 2 Shots (MMR & Varicella)? damage, and death. • Both options give the same protection. Mumps • One less shot with MMRV. • Causes fever, headache, swollen glands. • Children who got the first dose as MMRV have • Can lead to deafness, meningitis (infection of the brain had more fevers and fever-related seizures (about and spinal cord covering), infection of the pancreas, 1 in 1,250) than children who got the first dose as painful swelling of the testicles or ovaries, and, rarely, separate shots of MMR and varicella vaccines on death. the same day (about 1 in 2,500). Rubella (German Measles) Your doctor can give you more information, • Causes rash and mild fever; and can cause arthritis, including the Vaccine Information Statements for (mostly in women). MMR and Varicella vaccines.
    [Show full text]
  • Adult Vaccines
    What do flu, whooping cough, measles, shingles and pneumonia have in common? 1 They’re viruses that can make you very sick. 2 Vaccines can help prevent them. Protect yourself and those you care about. Get vaccinated at a network pharmacy near you. • Ask your pharmacist which vaccines are right for you. • Find out if your pharmacist can administer the recommended vaccinations. • Many vaccinations are covered by your plan at participating retail pharmacies. • Don’t forget to present your member ID card to the pharmacist at the time of service! The following vaccines are available and can be administered by pharmacists at participating network pharmacies: • Flu (seasonal influenza) • Meningitis • Travel Vaccines (typhoid, yellow • Tetanus/Diphtheria/Pertussis • Pneumonia fever, etc.) • Hepatitis • Rabies • Childhood Vaccines (MMR, etc.) • Human Papillomavirus (HPV) • Shingles/Zoster See other side for recommended adult vaccinations. The vaccinations you need ALL adults should get vaccinated for1: • Flu, every year. It’s especially important for pregnant women, older adults and people with chronic health conditions. • Tetanus, diphtheria and pertussis (whooping cough). Adults should get a one-time dose of the Tdap vaccine. It’s different from the tetanus vaccine (Td), which is given every 10 years. You may need additional vaccinations depending on your age1: Young adults not yet vaccinated need: Human papillomavirus (HPV) vaccine series (3 doses) if you are: • Female age 26 or younger • Male age 21 or younger • Male age 26 or younger who has sex with men, who is immunocompromised or who has HIV Adults born in the U.S. in 1957 or after need: Measles, mumps, rubella (MMR) vaccine2 Adults should get at least one dose of MMR vaccine, unless they’ve already gotten this vaccine or have immunity to measles, mumps and rubella Adults born in the U.S.
    [Show full text]
  • Viability of B. Typhosus in Stored Shell Oysters
    PUBLIC HEALTH REPORTS VOL. 40 APRIL 24, 1925 No. 17 VIABILITY OF B. TYPHOSUS IN STORED SHELL OYSTERS By CONRAD KINYOuN, Assistant Bacteriologist, hlygienic Laboratory, United Stztes Ptiblic Ilealti Serviee The object of this work was to determine whether oysters con- taminated with B. typhosuis and then stored unider uisual market conditions woul(l remain potentially infectious over a length of time sufficient to allow them to reach the consumer. Conflicting opinions are now current as to the length of time the causative agent of typhoid fever can remain viable in the oyster, and even as to whether the oyster can harbor the organisms at all. Obviouisly an oyster which harbors typhoidl organismns for as short a time as 24 hours becomes a potential infecting, agent for thlat time. Practi- cally it is of interest to know whether the time elapsing between the remov-al of the oyster from the bed and( actual consumption after passing through customary commercial channels is sufficient for oysters to rid themselves of possible infection. As early as 1603, oysters were incriminate(d in intestinal disor(lers, when suspicion was directed toward them by an illness of Henry IV of France (7). It was not uIntil the close of the nineteenth century, however, that oysters and shellfislh as agents of (lisease transmission receive(d particular attention. In October, 1894, Conn focused attention on the oyster by his investigation of the now famous Wesleyan outbreak, an(d thoughl only thlree outbreaks of typhoid fever were definitely traced to the oyster before 19,25, these stimulated wide interest and consequent study, with atten(lant epidemiological and bacteriological investigations.
    [Show full text]
  • Measles: Chapter 7.1 Chapter 7: Measles Paul A
    VPD Surveillance Manual 7 Measles: Chapter 7.1 Chapter 7: Measles Paul A. Gastanaduy, MD, MPH; Susan B. Redd; Nakia S. Clemmons, MPH; Adria D. Lee, MSPH; Carole J. Hickman, PhD; Paul A. Rota, PhD; Manisha Patel, MD, MS I. Disease Description Measles is an acute viral illness caused by a virus in the family paramyxovirus, genus Morbillivirus. Measles is characterized by a prodrome of fever (as high as 105°F) and malaise, cough, coryza, and conjunctivitis, followed by a maculopapular rash.1 The rash spreads from head to trunk to lower extremities. Measles is usually a mild or moderately severe illness. However, measles can result in complications such as pneumonia, encephalitis, and death. Approximately one case of encephalitis2 and two to three deaths may occur for every 1,000 reported measles cases.3 One rare long-term sequelae of measles virus infection is subacute sclerosing panencephalitis (SSPE), a fatal disease of the central nervous system that generally develops 7–10 years after infection. Among persons who contracted measles during the resurgence in the United States (U.S.) in 1989–1991, the risk of SSPE was estimated to be 7–11 cases/100,000 cases of measles.4 The risk of developing SSPE may be higher when measles occurs prior to the second year of life.4 The average incubation period for measles is 11–12 days,5 and the average interval between exposure and rash onset is 14 days, with a range of 7–21 days.1, 6 Persons with measles are usually considered infectious from four days before until four days after onset of rash with the rash onset being considered as day zero.
    [Show full text]
  • Measles Diagnostic Tool
    Measles Prodrome and Clinical evolution E Fever (mild to moderate) E Cough E Coryza E Conjunctivitis E Fever spikes as high as 105ºF Koplik’s spots Koplik’s Spots E E Viral enanthem of measles Rash E Erythematous, maculopapular rash which begins on typically starting 1-2 days before the face (often at hairline and behind ears) then spreads to neck/ the rash. Appearance is similar to “grains of salt on a wet background” upper trunk and then to lower trunk and extremities. Evolution and may become less visible as the of rash 1-3 days. Palms and soles rarely involved. maculopapular rash develops. Rash INCUBATION PERIOD Fever, STARTS on face (hairline & cough/coryza/conjunctivitis behind ears), spreads to trunk, Average 8-12 days from exposure to onset (sensitivity to light) and then to thighs/ feet of prodrome symptoms 0 (average interval between exposure to onset rash 14 day [range 7-21 days]) -4 -3 -2 -1 1234 NOT INFECTIOUS higher fever (103°-104°) during this period rash fades in same sequence it appears INFECTIOUS 4 days before rash and 4 days after rash Not Measles Rubella Varicella cervical lymphadenopathy. Highly variable but (Aka German Measles) (Aka Chickenpox) Rash E often maculopapular with Clinical manifestations E Clinical manifestations E Generally mild illness with low- Mild prodrome of fever and malaise multiforme-like lesions and grade fever, malaise, and lymph- may occur one to two days before may resemble scarlet fever. adenopathy (commonly post- rash. Possible low-grade fever. Rash often associated with painful edema hands and feet. auricular and sub-occipital).
    [Show full text]
  • Kaposi Sarcoma-Associated Herpesvirus Uals Were 2 to 16 Times More Likely to Develop Kaposi Sarcoma Than Were Uninfected Individuals
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Kaposi Sarcoma-Associated Herpesvirus uals were 2 to 16 times more likely to develop Kaposi sarcoma than were uninfected individuals. In some studies, the risk of Kaposi sar- CAS No.: none assigned coma increased with increasing viral load of KSHV (Sitas et al. 1999, Known to be a human carcinogen Newton et al. 2003a,b, 2006, Albrecht et al. 2004). Most KSHV-infected patients who develop Kaposi sarcoma have Also known as KSHV or human herpesvirus 8 (HHV-8) immune systems compromised either by HIV-1 infection or as a re- Carcinogenicity sult of drug treatments after organ or tissue transplants. The timing of infection with HIV-1 may also play a role in development of Ka- Kaposi sarcoma-associated herpesvirus (KSHV) is known to be a posi sarcoma. Acquiring HIV-1 infection prior to KSHV infection human carcinogen based on sufficient evidence from studies in hu- may increase the risk of epidemic Kaposi sarcoma by 50% to 100%, mans. This conclusion is based on evidence from epidemiological compared with acquiring HIV-1 infection at the same time as or after and molecular studies, which show that KSHV causes Kaposi sar- KSHV infection. Nevertheless, patients with the classic or endemic coma, primary effusion lymphoma, and a plasmablastic variant of forms of Kaposi sarcoma are not suspected of having suppressed im- multicentric Castleman disease, and on supporting mechanistic data. mune systems, suggesting that immunosuppression is not required KSHV causes cancer, primarily but not exclusively in people with for development of Kaposi sarcoma.
    [Show full text]
  • HIV Infection and AIDS
    G Maartens 12 HIV infection and AIDS Clinical examination in HIV disease 306 Prevention of opportunistic infections 323 Epidemiology 308 Preventing exposure 323 Global and regional epidemics 308 Chemoprophylaxis 323 Modes of transmission 308 Immunisation 324 Virology and immunology 309 Antiretroviral therapy 324 ART complications 325 Diagnosis and investigations 310 ART in special situations 326 Diagnosing HIV infection 310 Prevention of HIV 327 Viral load and CD4 counts 311 Clinical manifestations of HIV 311 Presenting problems in HIV infection 312 Lymphadenopathy 313 Weight loss 313 Fever 313 Mucocutaneous disease 314 Gastrointestinal disease 316 Hepatobiliary disease 317 Respiratory disease 318 Nervous system and eye disease 319 Rheumatological disease 321 Haematological abnormalities 322 Renal disease 322 Cardiac disease 322 HIV-related cancers 322 306 • HIV INFECTION AND AIDS Clinical examination in HIV disease 2 Oropharynx 34Neck Eyes Mucous membranes Lymph node enlargement Retina Tuberculosis Toxoplasmosis Lymphoma HIV retinopathy Kaposi’s sarcoma Progressive outer retinal Persistent generalised necrosis lymphadenopathy Parotidomegaly Oropharyngeal candidiasis Cytomegalovirus retinitis Cervical lymphadenopathy 3 Oral hairy leucoplakia 5 Central nervous system Herpes simplex Higher mental function Aphthous ulcers 4 HIV dementia Kaposi’s sarcoma Progressive multifocal leucoencephalopathy Teeth Focal signs 5 Toxoplasmosis Primary CNS lymphoma Neck stiffness Cryptococcal meningitis 2 Tuberculous meningitis Pneumococcal meningitis 6
    [Show full text]
  • Rubella (German Measles)
    Rubella (German Measles) Frequently Asked Questions What is rubella? Rubella is a common childhood disease caused by a virus. It can last one to five days and is generally a mild disease. Who gets rubella? Rubella can affect anyone of any age. Once you have had the infection you are usually immune and cannot catch it again. There are still cases of rubella around the world where populations are not vaccinated against the disease. How do people get rubella? When an infected person coughs or sneezes, the virus is released into the air and enters another person’s body through the nose or throat. Rubella is contagious seven days before and seven days after the rash appears. The rubella virus may also be found in the blood, urine, and stool of people who have the illness. What are the symptoms of rubella? Symptoms of rubella show up 14 to 21 days after exposure. Symptoms are often mild, and up to half of people infected with rubella virus have no symptoms at all. Symptoms include: • Low-grade fever • Swollen glands or lymph nodes • Rash • Small red bumps on the roof of the mouth (known as Forchheimer’s sign) • Dry, flaking skin • Swollen or bloodshot eyes • Stuffy nose • Joint pain and swelling (arthritis) • Loss of appetite • Headache Are there complications with a rubella virus infection? Rubella is usually a mild disease in children; adults tend to have more complications. The most serious danger of rubella is to pregnant women and the developing fetus. A miscarriage or premature delivery may occur in pregnant women.
    [Show full text]
  • Varicella (Chickenpox): Questions and Answers Q&A Information About the Disease and Vaccines
    Varicella (Chickenpox): Questions and Answers Q&A information about the disease and vaccines What causes chickenpox? more common in infants, adults, and people with Chickenpox is caused by a virus, the varicella-zoster weakened immune systems. virus. How do I know if my child has chickenpox? How does chickenpox spread? Usually chickenpox can be diagnosed by disease his- Chickenpox spreads from person to person by direct tory and appearance alone. Adults who need to contact or through the air by coughing or sneezing. know if they’ve had chickenpox in the past can have It is highly contagious. It can also be spread through this determined by a laboratory test. Chickenpox is direct contact with the fluid from a blister of a per- much less common now than it was before a vaccine son infected with chickenpox, or from direct contact became available, so parents, doctors, and nurses with a sore from a person with shingles. are less familiar with it. It may be necessary to perform laboratory testing for children to confirm chickenpox. How long does it take to show signs of chickenpox after being exposed? How long is a person with chickenpox contagious? It takes from 10 to 21 days to develop symptoms after Patients with chickenpox are contagious for 1–2 days being exposed to a person infected with chickenpox. before the rash appears and continue to be conta- The usual time period is 14–16 days. gious through the first 4–5 days or until all the blisters are crusted over. What are the symptoms of chickenpox? Is there a treatment for chickenpox? The most common symptoms of chickenpox are rash, fever, coughing, fussiness, headache, and loss of appe- Most cases of chickenpox in otherwise healthy children tite.
    [Show full text]
  • Vaccine Information Statement
    VACCINE INFORMATION STATEMENT Many Vaccine Information Statements are available in Spanish and other languages. MMRV (Measles, Mumps, Rubella, and See www.immunize.org/vis Hojas de información sobre vacunas están Varicella) Vaccine: What You Need to Know disponibles en español y en muchos otros idiomas. Visite www.immunize.org/vis 1 Why get vaccinated? 2 MMRV Vaccine Measles, mumps, rubella, and varicella are viral diseases that can MMRV vaccine may be given to children 12 months through 12 have serious consequences. Before vaccines, these diseases were years of age. Two doses are usually recommended: very common in the United States, especially among children. First dose: 12 through 15 months of age They are still common in many parts of the world. Second dose: 4 through 6 years of age Measles A third dose of MMR might be recommended in certain mumps Measles virus causes symptoms that can include fever, cough, outbreak situations. runny nose, and red, watery eyes, commonly followed by a rash There are no known risks to getting MMRV vaccine at the same that covers the whole body. time as other vaccines. Measles can lead to ear infections, diarrhea, and infection of the lungs (pneumonia). Rarely, measles can cause brain damage or Instead of MMRV, some children 12 months death. through 12 years of age might get 2 separate Mumps shots: MMR (measles, mumps and rubella) and Mumps virus causes fever, headache, muscle aches, tiredness, chickenpox (varicella). MMRV is not licensed for loss of appetite, and swollen and tender salivary glands under the people 13 years of age or older.
    [Show full text]
  • Oklahoma Disease Reporting Manual
    Oklahoma Disease Reporting Manual List of Contributors Acute Disease Service Lauri Smithee, Chief Laurence Burnsed Anthony Lee Becky Coffman Renee Powell Amy Hill Jolianne Stone Christie McDonald Jeannie Williams HIV/STD Service Jan Fox, Chief Kristen Eberly Terrainia Harris Debbie Purton Janet Wilson Office of the State Epidemiologist Kristy Bradley, State Epidemiologist Public Health Laboratory Garry McKee, Chief Robin Botchlet John Murray Steve Johnson Table of Contents Contact Information Acronyms and Jargon Defined Purpose and Use of Disease Reporting Manual Oklahoma Disease Reporting Statutes and Rules Oklahoma Statute Title 63: Public Health and Safety Article 1: Administration Article 5: Prevention and Control of Disease Oklahoma Administrative Code Title 310: Oklahoma State Department of Health Chapter 515: Communicable Disease and Injury Reporting Chapter 555: Notification of Communicable Disease Risk Exposure Changes to the Communicable Disease and Injury Reporting Rules To Which State Should You Report a Case? Public Health Investigation and Disease Detection of Oklahoma (PHIDDO) Public Health Laboratory Oklahoma State Department of Health Laboratory Services Electronic Public Health Laboratory Requisition Disease Reporting Guidelines Quick Reference List of Reportable Infectious Diseases by Service Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS) Anthrax Arboviral Infection Bioterrorism – Suspected Disease Botulism Brucellosis Campylobacteriosis CD4 Cell Count < 500 Chlamydia trachomatis,
    [Show full text]
  • WHO African Regional Measles and Rubella Surveillance Guidelines
    AFRICAN REGIONAL GUIDELINES FOR MEASLES AND RUBELLA SURVEILLANCE WHO Regional Office for Africa Revised April 2015 African Regional guidelines for measles and rubella surveillance- Draft version April 2015. 1 Contents ACRONYMS ............................................................................................................................................. 4 I. INTRODUCTION ............................................................................................................................... 5 II. MEASLES DISEASE ........................................................................................................................... 5 i. Epidemiology of measles ............................................................................................................ 5 ii. Clinical features of measles ........................................................................................................ 6 iii. Complications of Measles ........................................................................................................... 7 iv. Measles Immunity ....................................................................................................................... 8 III. RUBELLA DISEASE ........................................................................................................................ 9 i. Epidemiology and clinical features: ............................................................................................ 9 ii. Congenital Rubella Syndrome ....................................................................................................
    [Show full text]